Lupus News and Research

Latest Lupus News and Research

Report provides critical strategic insight for companies with a stake in the market for rheumatology therapies

MedPredict Market Research, a global provider of pharmaceutical competitive intelligence and market research, has published a new report providing critical strategic insight for companies with a stake in the market for rheumatology therapies, including rheumatoid arthritis (RA) and lupus.

7 Nov 2009

Study on asbestos-related diseases in Libby launched

Over nearly a century, thousands of residents and workers in Libby, MT, have been exposed to asbestos-contaminated vermiculite ore, leading to markedly higher rates of lung disease and autoimmune disorders, and causing to Libby in 2002 to be added to the federal Environmental Protection Agency's "National Priorities List."

4 Nov 2009

Smokers with systemic lupus erythematosus at greater risk of skin damage and rashes

As if there weren't enough reasons to stop smoking, a team of researchers at the Research Institute of the McGill University Health Centre (RI-MUHC) have just found another. A study led by Dr. Christian A Pineau, Co-Director of the Lupus and Vasculitis clinic at the MUHC, has clearly linked skin damage and rashes to smoking in people with systemic lupus erythematosus (SLE). The study was published in a recent issue of the Journal of Rheumatology.

3 Nov 2009

Interim data from Schering-Plough's narlaprevir Phase IIa study

Schering-Plough Corporation reported that interim results from an ongoing Phase IIa study of narlaprevir (SCH 900518), its investigational, once-daily protease inhibitor, demonstrated potent antiviral activity in treatment-naive patients with chronic hepatitis C virus (HCV) genotype 1.

3 Nov 2009

SQI Diagnostics' SQiDworks automated platform and IgXPLEX RA assay receive FDA marketing clearance

SQI Diagnostics Inc., a medical systems automation company focused on evolving laboratory-based biomarker testing, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Company's automated SQiDworks(TM) Diagnostics Platform and its multiplexed IgXPLEX(TM) rheumatoid arthritis (RA) assay for marketing in the United States.

2 Nov 2009

LRI and lupus organizations congratulate HGS and GlaxoSmithKline for achieving historical landmark

The Lupus Research Institute (LRI) and its National Coalition of state and local lupus organizations congratulate Human Genome Sciences (HGS) and GlaxoSmithKline for achieving an historical landmark - the second positive phase 3 clinical trial of Benlysta (belimumab), the first successfully tested new drug developed specifically for people with systemic lupus.

2 Nov 2009

HGS and GSK announce results from phase III clinical trials of BENLYSTA

Human Genome Sciences (HGS) and GlaxoSmithKline (GSK) today announced positive results from BLISS-76, the second of two large-scale phase III clinical trials of BENLYSTA(TM) (belimumab) for treating systemic lupus. A full presentation of results from BLISS-52 was recently shared at the 73rd Annual Scientific meeting of the American College of Rheumatology. Both trials succeeded in meeting their primary endpoints, which should make BENLYSTA eligible for approval by the U.S. Food and Drug Administration (FDA).

2 Nov 2009

BENLYSTA meets primary endpoint in BLISS-76 trial for systemic lupus erythematosus

Human Genome Sciences, Inc. and GlaxoSmithKline PLC (GSK) today announced that BENLYSTA™ (belimumab) met the primary endpoint in BLISS-76, the second of two pivotal Phase 3 trials in seropositive patients with systemic lupus erythematosus (SLE). BLISS-76 study results through 52 weeks showed that belimumab 10 mg/kg plus standard of care achieved a statistically significant improvement in patient response rate as measured by the SLE Responder Index at Week 52, compared with placebo plus standard of care.

2 Nov 2009

Lupus patients rarely develop kidney disorders after a kidney transplant

Individuals with a history of lupus who receive a kidney transplant rarely develop the serious inflammatory condition lupus nephritis in their new organ, according to a paper being presented at the American Society of Nephrology's 42nd Annual Meeting and Scientific Exposition in San Diego, CA.

2 Nov 2009

Schering-Plough receives FDA complete response letter regarding PEGINTRON

Schering-Plough Corp. announced the U.S. Food and Drug Administration (FDA) has issued a complete response letter to the company's supplemental Biologics License Application regarding PEGINTRON® (pegylated interferon alfa-2b) for the adjuvant treatment of patients with stage III malignant melanoma after complete lymphadenectomy.

31 Oct 2009

Human Genome Sciences declares financial results for third quarter 2009; reports increased revenue growth

Human Genome Sciences, Inc. today announced financial results for the quarter ended September 30, 2009, and provided highlights of recent key developments.

30 Oct 2009

Steroid-induced osteoporosis can now be treated with Teriparatide

A recent study determined glucocorticoid-induced osteoporosis (OP) is now treatable with Teriparatide, a synthetic form of the human parathyroid hormone. Researchers found patients with glucocorticoid-induced OP who were treated with teriparatide for 36 months had a greater increase in bone mineral density (BMD) and fewer new vertebral fractures than those treated with alendronate.

29 Oct 2009

New data from CIMZIA WELCOME trial to be presented at the ACG meeting

According to new results from the WELCOME trial, exploratory data analyzing the impact of treatment with CIMZIA(®) (certolizumab pegol) - the only PEGylated anti-TNF (alpha) (Tumor Necrosis Factor alpha) - administered either every two weeks or every four weeks, showed that the majority of Crohn's disease patients in both dosing groups experienced no hospitalizations and surgical procedures during the course of the 26-week study.

28 Oct 2009

New data from efficacy study of CIMZIA in Crohn's disease patients presented

New data from an open-label extension study evaluating the long-term safety and efficacy of CIMZIA® (certolizumab pegol) in moderate to severe Crohn's disease patients demonstrate that 82 percent of patients actively treated with CIMZIA - the only PEGylated anti-TNF-alpha (Tumor Necrosis Factor alpha) - remained in long-term remission without dose escalation up to 3.5 years.

27 Oct 2009

Inhibikase Therapeutics to illustrate the utility of IkT-001 and IkT-041 to treat multiple infectious diseases

Inhibikase Therapeutics, a specialty pharmaceutical company based in Atlanta, Georgia, will discuss simultaneous antiviral and antibacterial activity from small molecule agents at the 2009 BIOCOM Investor Conference. Employing a host-factor targeted approach, Inhibikase will illustrate the utility of IkT-001 and IkT-041 to treat multiple infectious diseases in humans.

27 Oct 2009

Scientists discover new way to help save lives threatened by traumatic injuries

A discovery by scientists at the Oklahoma Medical Research Foundation could help save lives threatened by traumatic injuries like those sustained in car crashes or on the battlefield. The work also holds potential for treating severe infectious diseases and diabetes.

26 Oct 2009

New guidelines from American Academy of Dermatology for treatment of psoriasis with ultraviolet light therapy

Based on an extensive review of the highest quality scientific literature on psoriasis and the opinion of recognized psoriasis experts, the American Academy of Dermatology (Academy) has released new guidelines of care for the management and treatment of psoriasis with ultraviolet (UV) light therapy, also known as phototherapy. Recommendations for the use of the most common forms of UV light therapy, as stand-alone treatments or in conjunction with other therapies, were outlined, including patient considerations.

23 Oct 2009

Advisory Committee on Immunization Practices supports the permissive use of GARDASIL

Merck & Co., Inc. announced today that the U.S. Centers for Disease Control and Prevention’s (CDC’s) Advisory Committee on Immunization Practices (ACIP) supports the permissive use of GARDASIL® [Human Papillomavirus Quadrivalent (Types 6, 11, 16 and 18) Vaccine, Recombinant] for boys and young men ages 9 to 26, which means that GARDASIL may be given to males ages 9 to 26 to reduce the likelihood of acquiring genital warts at the discretion of the patient's health care provider.

22 Oct 2009

SIMPONI treatment results in greater inhibition of structural damage in arthritis patients

Phase 3 data reported for the first time show that once every four week subcutaneous injections of SIMPONI(TM) (golimumab) resulted in significantly greater inhibition of structural damage compared with placebo plus methotrexate in patients with active rheumatoid arthritis (RA) and active psoriatic arthritis (PsA).

20 Oct 2009

Human Genome Sciences and GlaxoSmithKline to present Phase 3 trial results of BENLYSTA

Human Genome Sciences, Inc. and GlaxoSmithKline PLC (GSK) today announced the full presentation of results from BLISS-52, the first of two pivotal Phase 3 trials of BENLYSTA™ (belimumab) in seropositive patients with systemic lupus erythematosus (SLE).

20 Oct 2009

Lupus News and Research

Latest Lupus News and Research

Report provides critical strategic insight for companies with a stake in the market for rheumatology therapies

Study on asbestos-related diseases in Libby launched

Smokers with systemic lupus erythematosus at greater risk of skin damage and rashes

Interim data from Schering-Plough's narlaprevir Phase IIa study

SQI Diagnostics' SQiDworks automated platform and IgXPLEX RA assay receive FDA marketing clearance

LRI and lupus organizations congratulate HGS and GlaxoSmithKline for achieving historical landmark

HGS and GSK announce results from phase III clinical trials of BENLYSTA

BENLYSTA meets primary endpoint in BLISS-76 trial for systemic lupus erythematosus

Lupus patients rarely develop kidney disorders after a kidney transplant

Schering-Plough receives FDA complete response letter regarding PEGINTRON

Human Genome Sciences declares financial results for third quarter 2009; reports increased revenue growth

Steroid-induced osteoporosis can now be treated with Teriparatide

New data from CIMZIA WELCOME trial to be presented at the ACG meeting

New data from efficacy study of CIMZIA in Crohn's disease patients presented

Inhibikase Therapeutics to illustrate the utility of IkT-001 and IkT-041 to treat multiple infectious diseases

Scientists discover new way to help save lives threatened by traumatic injuries

New guidelines from American Academy of Dermatology for treatment of psoriasis with ultraviolet light therapy

Advisory Committee on Immunization Practices supports the permissive use of GARDASIL

SIMPONI treatment results in greater inhibition of structural damage in arthritis patients

Human Genome Sciences and GlaxoSmithKline to present Phase 3 trial results of BENLYSTA

Redefining control and consistency in anaerobic microbiome workflows

AI in Healthcare: How generative tools are transforming clinical practice

The future of automation: Machine learning–driven hepatocyte and organoid counting

Lupus News and Research

Latest Lupus News and Research

Redefining control and consistency in anaerobic microbiome workflows

AI in Healthcare: How generative tools are transforming clinical practice

The future of automation: Machine learning–driven hepatocyte and organoid counting

Newsletters you may be interested in